Health Care [ 9/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer.
The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.02 Decreased by -108.33% | -0.05 Increased by +60.00% |
| May 14, 25 | -0.18 Increased by 0.00% | -0.17 Decreased by -9.09% |
| Mar 20, 25 | -0.05 Increased by +79.17% | -0.03 Decreased by -68.35% |
| Nov 13, 24 | -0.01 Increased by +95.00% | -0.01 |
| Aug 12, 24 | 0.24 Increased by +204.35% | -0.07 Increased by +442.86% |
| May 15, 24 | -0.18 Decreased by -1.90 K% | -0.10 Decreased by -80.00% |
| Mar 6, 24 | -0.24 Decreased by -33.33% | -0.10 Decreased by -140.00% |
| Nov 8, 23 | -0.20 Increased by +16.67% | -0.12 Decreased by -66.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 13.68 M Decreased by -89.33% | -30.34 M Decreased by -143.64% | Decreased by -221.83% Decreased by -509.17% |
| Mar 31, 25 | 7.29 M Increased by +28.30% | -47.58 M Increased by +1.89% | Decreased by -653.18% Increased by +23.54% |
| Dec 31, 24 | 3.22 M Increased by +1.28 K% | -74.22 M Decreased by -53.55% | Decreased by -2.30 K% Increased by +88.90% |
| Sep 30, 24 | 40.90 M Increased by +458.83% | -17.62 M Increased by +61.37% | Decreased by -43.07% Increased by +93.09% |
| Jun 30, 24 | 128.23 M Increased by +2.40 K% | 69.52 M Increased by +425.03% | Increased by +54.22% Increased by +113.00% |
| Mar 31, 24 | 5.68 M Decreased by -88.07% | -48.50 M Decreased by -4.78 K% | Decreased by -854.23% Decreased by -39.35 K% |
| Dec 31, 23 | 233.01 K Decreased by -97.89% | -48.33 M Decreased by -65.24% | Decreased by -20.74 K% Decreased by -7.72 K% |
| Sep 30, 23 | 7.32 M Increased by +4.45% | -45.60 M Decreased by -10.09% | Decreased by -623.05% Decreased by -5.40% |